Drd3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@schwartz1993] |-----------|-------| [@kitzerow2000] | Protein Name | Dopamine Receptor D3 | [@garzn2009] | Gene Symbol | [drd3](/proteins/drd3-protein) | | UniProt ID | [P35462](https://www.uniprot.org/uniprot/P35462) | | Molecular Weight | ~95-130 kDa (glycosylated) | | Subcellular Localization | Plasma membrane, dendrites, synapses | | Protein Family | D2-like dopamine receptor family (GPCR) | | Signal Transduction | Gi/o protein-coupled, inhibits adenylate cyclase |
</div>}
Overview
The Dopamine Receptor D3 (DRD3) is a G protein-coupled receptor encoded by the [DRD3](/proteins/drd3-protein) gene. It belongs to the D2-like family of dopamine receptors and is predominantly expressed in the limbic system, making it a key player in reward processing, emotional regulation, and motivational behavior. DRD3 has attracted significant interest in neurodegenerative and psychiatric research due to its involvement in Parkinson's disease, restless leg syndrome, and neuropsychiatric disorders.
Structure
DRD3 contains the classic seven transmembrane domain architecture typical of GPCRs:
...
Dopamine Receptor D3 Protein
Introduction
Drd3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@schwartz1993] |-----------|-------| [@kitzerow2000] | Protein Name | Dopamine Receptor D3 | [@garzn2009] | Gene Symbol | [drd3](/proteins/drd3-protein) | | UniProt ID | [P35462](https://www.uniprot.org/uniprot/P35462) | | Molecular Weight | ~95-130 kDa (glycosylated) | | Subcellular Localization | Plasma membrane, dendrites, synapses | | Protein Family | D2-like dopamine receptor family (GPCR) | | Signal Transduction | Gi/o protein-coupled, inhibits adenylate cyclase |
</div>}
Overview
The Dopamine Receptor D3 (DRD3) is a G protein-coupled receptor encoded by the [DRD3](/proteins/drd3-protein) gene. It belongs to the D2-like family of dopamine receptors and is predominantly expressed in the limbic system, making it a key player in reward processing, emotional regulation, and motivational behavior. DRD3 has attracted significant interest in neurodegenerative and psychiatric research due to its involvement in Parkinson's disease, restless leg syndrome, and neuropsychiatric disorders.
Structure
DRD3 contains the classic seven transmembrane domain architecture typical of GPCRs:
N-terminal extracellular domain: Contains glycosylation sites for proper folding and trafficking
Transmembrane domains (TM1-TM7): Seven alpha-helices that span the plasma membrane
Three extracellular loops (ECL1-ECL3): Involved in ligand binding, particularly dopamine and therapeutic compounds
Three intracellular loops (ICL1-ICL3): Couple to G proteins for signal transduction
C-terminal intracellular tail: Contains serine/threonine residues for phosphorylation and desensitization
The DRD3 receptor has higher affinity for dopamine than DRD2, allowing it to be activated at lower neurotransmitter concentrations.
Normal Function
DRD3 mediates the following physiological functions:
Inhibition of adenylate cyclase: Couples to Gi/o proteins, reducing cAMP production
Modulation of ion channels: Activates inward-rectifier potassium channels (GIRKs), hyperpolarizing [neurons](/entities/neurons)
Reward processing: High expression in nucleus accumbens and ventral tegmental area
Emotional regulation: Limbic system expression contributes to anxiety and mood modulation
Motor control: Basal ganglia expression influences movement initiation and inhibition
Cognitive function: Prefrontal [cortex](/brain-regions/cortex) expression affects working memory and decision-making
Role in Neurodegeneration
Parkinson's Disease
DRD3 expression is altered in Parkinson's disease, particularly in the striatum and limbic regions. Post-mortem studies show increased DRD3 binding in the nucleus accumbens of PD patients, which may contribute to non-motor symptoms including depression, anxiety, and impulse control disorders. DRD3 antagonists have been investigated for treating levodopa-induced dyskinesias.
Restless Leg Syndrome (RLS)
DRD3 is strongly implicated in restless leg syndrome pathogenesis. Genetic studies have identified DRD3 variants associated with RLS susceptibility. The receptor's role in modulating dopaminergic tone in the basal ganglia contributes to the characteristic urge to move during rest.
Schizophrenia
While not a primary neurodegenerative disorder, DRD3 dysfunction contributes to psychotic symptoms. Antipsychotic drugs target DRD3 along with DRD2, and certain DRD3 variants are associated with treatment response.
Therapeutic Implications
| Drug Class | Examples | Mechanism | Status | |-----------|----------|-----------|--------| | DRD3 Agonists | Pramipexole, Rotigotine | Activate receptor for therapeutic effect | FDA approved for PD | | DRD3 Antagonists | SB-277011A | Block receptor signaling | Preclinical/Research | | Partial Agonists | Cariprazine | Balanced receptor activation | FDA approved for schizophrenia |
Research Directions
Selective DRD3 agonists for neuroprotection without motor side effects
Allosteric modulators for finer control of receptor activity
PET ligands for imaging DRD3 density in vivo
Gene therapy approaches for long-term modulation
Background
The study of Drd3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.